These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2932183)

  • 1. Identification and quantification of metabolite conjugates of activated cyclophosphamide and ifosfamide with mesna in urine by ion-pair extraction and fast atom bombardment mass spectrometry.
    Manz I; Dietrich I; Przybylski M; Niemeyer U; Pohl J; Hilgard P; Brock N
    Biomed Mass Spectrom; 1985 Sep; 12(9):545-53. PubMed ID: 2932183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V; Wagner T
    Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
    Brock N
    Recent Results Cancer Res; 1980; 74():270-8. PubMed ID: 6777836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
    J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
    Brock N; Pohl J
    IARC Sci Publ; 1986; (78):269-79. PubMed ID: 3108156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
    Brock N; Pohl J; Stekar J
    J Cancer Res Clin Oncol; 1981; 100(3):311-20. PubMed ID: 6792207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the uroprotector sodium 2-mercaptoethane sulfonate (Mesna) on the proliferation of the bladder urothelium in the rat after administration of cyclophosphamide.
    Kunze E; Köhnecke B; Engelhardt W; Steinröder H; Brock N; Pohl J
    Urol Int; 1984; 39(2):61-7. PubMed ID: 6426112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).
    Brock N; Pohl J; Stekar J; Scheef W
    Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1377-87. PubMed ID: 6819957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
    Brock N; Stekar J
    Arzneimittelforschung; 1982; 32(5):486-7. PubMed ID: 6809014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro/in vivo effects of Mesna on the genotoxicity and toxicity of cyclophosphamide--a study aimed at clarifying the mechanism of Mesna's anticarcinogenic activity.
    Pool BL; Bos RP; Niemeyer U; Theuws JL; Schmähl D
    Toxicol Lett; 1988 Apr; 41(1):49-56. PubMed ID: 3128896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide and mesna.
    Schoenike SE; Dana WJ
    Clin Pharm; 1990 Mar; 9(3):179-91. PubMed ID: 2107997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
    Araujo CE; Tessler J
    Eur J Cancer Clin Oncol; 1983 Feb; 19(2):195-201. PubMed ID: 6402369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. False-positive ketone tests: a bedside measure of urinary mesna.
    Goren MP; Pratt CB
    Cancer Chemother Pharmacol; 1990; 25(5):371-2. PubMed ID: 2106398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.
    Brock N; Stekar J; Pohl J; Niemeyer U; Scheffler G
    Arzneimittelforschung; 1979; 29(4):659-61. PubMed ID: 114192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity.
    Sangster G; Kaye SB; Calman KC; Dalton JF
    Eur J Cancer Clin Oncol; 1984 Mar; 20(3):435-6. PubMed ID: 6423391
    [No Abstract]   [Full Text] [Related]  

  • 16. Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing.
    Jones MS; Murrell RD; Shaw IC
    Eur J Cancer Clin Oncol; 1985 May; 21(5):553-5. PubMed ID: 3924627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical overview of mesna.
    Burkert H
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():175-81. PubMed ID: 6414692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetylcysteine and sodium 2-mercaptoethane sulfonate as sources of urinary thiol groups in the rat.
    Ormstad K; Ohno Y
    Cancer Res; 1984 Sep; 44(9):3797-800. PubMed ID: 6430554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). Experimental studies and clinical consequences].
    Schmähl D; Habs M; Tacchi AM
    Urologe A; 1984 Sep; 23(5):291-6. PubMed ID: 6438859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of Mesna (2-mercaptoethane sulfonate) with the mutagenicity of cyclophosphamide in vitro and in vivo.
    Lähdetie J; Räty R; Sorsa M
    Mutat Res; 1990 Sep; 245(1):27-32. PubMed ID: 2118231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.